DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wrvp9r/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- A snapshot of the global therapeutic scenario for Dementia.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dementia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dementia.
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned:
Abbott Laboratories
GlaxoSmithKline plc
Sylentis
Astellas Pharma Inc.
Eisai Co., Ltd.
Kowa Company, Ltd.
Merz GmbH & Co. KGaA
Neuren Pharmaceuticals Limited
ProteoTech, Inc.
The University of Tokyo
WhanIn Pharmaceutical Co., Ltd.
SYGNIS Pharma AG
Allon Therapeutics Inc.
MediPost Co., Ltd.
e-Therapeutics plc
Oryzon
TauRx Therapeutics Ltd
Acumen Pharmaceuticals, Inc.
BIOALVO S.A.
IMMD Inc.
Neurimmune Therapeutics AG
BioArctic Neuroscience AB
Intellect Neurosciences, Inc.
Sparsha Pharma International Pvt. Ltd.
Tautatis Incorporated
Stelic Institute & Co.
Varinel, Inc.
For more information visit http://www.researchandmarkets.com/research/wrvp9r/dementia
Source: Global Markets Direct